chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Several hours after receiving her second Moderna vaccine, she developed a burning sensation in her face.  The next day she went to the urgent care with edema and erythema of her face (sparing lips and tongue) and was diagnosed w/ urticara, and received IM Solumedrol and IM Benadryl and was advised to take oral diphenhydramine, Motrin and Tylenol upon discharge. 2 days later she went to the ER w/ persistent symptoms and was diagnosed w/ erysipelas, vaccine reaction and ARB allergy (though she continued to take her ARB) and was treated w/ Benadryl and Clindamycin.  Symptoms resolved.  She never had lip or tongue swelling or respiratory distress.
Child said leg hurt, nothing seen, mom gave APAP; Child began jerking all over 4min, extra salivation, t102, acted sleepy p/episode;
Diffuse urticarial rash involving right axilla and over bilateral  shoulders, developed intense chest pressure and squeezing, heart racing  and when those symptoms resolved pt. became very weak. Of note pt. stated was lightheaded for 15 mins after receiving the vaccine
I had chest pain for a day  or more before going to the emergency room where it was co firmed I was having a heart attack later confirmed to be caused by myocarditis
pain; fever of 101F; Chills; Headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (pain), PYREXIA (fever of 101F), CHILLS (Chills) and HEADACHE (Headache) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 058E21A and 052E21A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Sep-2021, the patient experienced PAIN (pain), PYREXIA (fever of 101F), CHILLS (Chills) and HEADACHE (Headache). The patient was treated with IBUPROFEN (MOTRIN [IBUPROFEN]) for Pain and Fever, at an unspecified dose and frequency. At the time of the report, PAIN (pain), PYREXIA (fever of 101F), CHILLS (Chills) and HEADACHE (Headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-Sep-2021, Body temperature: 101f (High) Fever of 101F.         No concomitant medications were provided
Rash on scapula and shoulder area/trunk of arm/ rash over whole body and bottom of feet; This is a non-serious spontaneous case from initially received from a pharmacist on 05-Nov-2018, concerning a 20-year-old, adult female patient.  On 24-Sep-2018, the patient was administered Afluria Quadrivalent (influenza vaccine, batch number: YF38607, expiry date: 30-Jun-2019, dose, route of administration and anatomical location: not reported) for an unknown indication.  On an unspecified date in Sep-2018, after vaccination, the patient developed rash on her scapula and shoulder area which had spread to her trunk of her arm.  On 26-Sep-2018, the patient was advised to seek care with her primary care physician and was prescribed a Medrol (methylprednisolone) dose pack. The patient was still having rash all over whole body and bottom of feet.  At the time of this report, the patient had not recovered from the event.  Non-significant case amendment (05-Nov-2018): The onset latency in the case comment was changed from 'on an unspecified date' to 'within two days' in the analysis tab. No changes were made in narrative.  Non-significant follow-up received on 22-Jan-2019: This case was considered as lost to follow up as the reporter could not be contacted to gather further information. Added Med Info Number (SEQ18-07541) in the additional information tab. No amendment done in narrative.; Reporter's Comments: A 20-year-old, female patient developed rash all over within two days of administration of Afluria Quadrivalent. The company assessed the causality of the event as related to the suspect vaccine due to plausible temporal relationship between the events and the suspect vaccine.
illness w/focal sz & encephalopathy best described as acute disseminated encephalomyelitis;
No adverse effects reported; dose of GARDASIL may have been administered subcutaneously; dose of GARDASIL may have been administered subcutaneously; This spontaneous report was received from a patient of an unknown age and gender, who is also a physician. Information about the patient's medical history, concurrent conditions and concomitant medications was not provided.  On an unspecified date in April 2019, the patient was vaccinated with quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) for prophylaxis (strength, dose number, anatomical location of vaccination, lot number and expiration date were not provided) that may had been administered subcutaneously (circumstance or information capable of leading to medication error and incorrect route of product administration). No adverse effects were reported.
received her 1st dose of the Moderna Covid-19 vaccine in January 2021. She's here to get her 2nd dose today.; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received her 1st dose of the Moderna Covid-19 vaccine in January 2021. She's here to get her 2nd dose today.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Sep-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received her 1st dose of the Moderna Covid-19 vaccine in January 2021. She's here to get her 2nd dose today.). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (received her 1st dose of the Moderna Covid-19 vaccine in January 2021. She's here to get her 2nd dose today.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported by reporter Treatment information was not provided
Burning sensation.  Started in left side of neck went to left shoulder then spread out all over body.  Headache and fever
Information has been received from an office manager at physician's office concerning a female who on an unspecified date was vaccinated with a dose of GARDASIL (Lot number not provided).  No concomitant medications were reported.  The office manager reported that the physician had a patient who reported to him that she developed temporary blindness after receiving GARDASIL.  The onset date was unknown.  The patient was not vaccinated by this physician's office.  The patient did go to the ER for treatment.  The patient's sight did return.  There was no product complaint.  Upon internal review the temporary blindness was determined to be an other important medical event.  Additional information has been requested.
8/27/2018-onset of rash, left lower thoracic area, crossed midline across left flank, some papules on abdomen, small area of left shoulder, also (R) glute. 8/18/18-pain, fever up to 100.3 a few d later, noticeable fatigue; nasal congestion. No pain.
This spontaneous report as received from a healthcare worker concerning an unknown number of patients of an unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date the patients were vaccinated with a dose of ROTATEQ (dose, frequency, strength, lot number, expiration date and route were not reported). Co-suspect and concomitant therapies were not reported. The healthcare worker reported that on an unknown date, an improperly stored ROTATEQ may have all been administered. The healthcare worker reported that the ROTATEQ were exposed to a temperature of 1.5C for 25 minutes. No adverse effect reported. Additional information has been requested. There are one (1) of five (5) reports from the same reporter. (MARSS 1405USA012173, 1406USA000568, 1406USA000569, 1406USA000570 and 1406USA000571).
This case was reported by a other health professional via call center representative and described the occurrence of injection site pain in a 17-year-old patient who received BEXSERO (batch number 151401A, expiry date 31st December 2016). Concomitant products included MENVEO. On 1st August 2016, the patient received BEXSERO. On 1st August 2016, less than a day after receiving BEXSERO, the patient experienced injection site pain (serious criteria other: serious as per reporter). On 7th August 2016, the patient experienced injection site swelling. On an unknown date, the outcome of the injection site pain and injection site swelling were unchanged. It was unknown if the reporter considered the injection site pain and injection site swelling to be related to BEXSERO. Additional details were provided as follows: The age at vaccination was not reported. The patient experienced soreness and bump in the arm of the BEXSERO injection and MENVEO was administered in the opposite arm. At the time of reporting, the patient visited the other healthcare professional's office for a consultation about the adverse events. The other healthcare professional agreed to have follow up with them via mail to fill out reminder of the report.
Vaccine 10/13/08 4 pm.  10/13/08 9 pm pain, heat, itching at injection site.  10/14 AM swelling, pain, heat, itching.  ? cellulitis.  BENADRYL 50 mg and sent to ER.  Received I.V. vancomycin.  Admitted for 24 hours +.  Dc'd 10/18/08 on P.O antibiotics (KEFLEX) 10/20/08.  Denies S/S at this time. 11/17/08-records received 11/17/08-presented to ED with C/O fever and increased pain, decreased range of motion in right arm. Nausea and vomiting.  DX Right upper extremity cellulitis.
livedoid vasculopathy, possibly antiphospholipid antibody syndrome  covid vaccine 9 mar 2021, moderna, in Apr 2021 began getting LE nodules that progressed to leg ulceration, EXTENSIVE necrotic BLE wounds covering much of thighs, and below knee as well, reticular livedoid rash BLEs and arm, had ?covid arm? w/ softball sized welt after first covid shot, also on Adderall and OCPs, dx?d w/ thrombotic vasculopathy and anticoagulation begun Sep 2021, reports of + LAC noted after 2nd shot at outside hospital, repeat pending of hex, b2gp, ACA and DRVVT neg here Sep 2021. h/o 3 early miscarriages but no other clotting.
Complaints of redness & swelling 1 week after second dose of Anthrax. No reaction with first Anthrax vaccine. Lesions left arm proximal 10 cm in size. Prescribed Cephalexin, BENADRYL & Ibuprofen.
Pt's left upper arm became red and swollen from axilla to elbow with multiple vesicles approximately 5 cm circumference around injection site. Slight discoloration around injection site.
FIRST WEEK: Swollen, sore arm;  Lethargy, muscle aches, dizziness, headache SECOND WEEK:  Rash & itching at & around the injection site, which continued to be swollen.  At maximum,  rash was red, 5" long, and 2 1/2' wide. Itchiness was worst Days 9 -11 and Days 15- 16. Resolved on Day 20.
RECEIVED LESS THAN 0.5 ML OF VACCINE AS A BOOSTER DOSE (0.3 ML); OFF LABEL USE; This spontaneous report received from a health care professional concerned a 53 year old old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient was previously received covid-19 vaccine ad26. cov2. s from unspecified manufacturer (form of admin, route of admin, and batch number were not reported), 1 total, dose was not reported for prophylactic vaccination (Dose number in series 1). It was unknown whether patient had any adverse events. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 213D21A, expiry: 11-APR-2022) with dose less than 0.5 ml (approximately around 0.3ml) (Dose number in series 2) 1 total, administered on 01-DEC-2021 to left arm for prophylactic vaccination which was an off label use as patient received less than 0.5ml of the Janssen covid-19 vaccine as a booster dose (LLT: Vaccine under dose). No concomitant medications were reported. As per the report, the HCP withdrew 8 doses of the Janssen Covid-19 vaccine from 5 vials and 7 doses from 1 vial which injected into 48 individuals. When the caller had a discussion with that HCP, mentioned that he/she injected 0.5mL but the caller mentioned that the math (she arrived at that by dividing 2.5mL by 5 doses) did prove that they received approximately around 0.3mL (both events dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the received less than 0.5 ml of vaccine as a booster dose (0.3 ml) and off label use was not reported. This report was non-serious. This case, from the same reporter is linked to 20211210684, 20211210197, 20211210409, 20211210067, 20211209551, 20211210058, 20211210160, 20211209843, 20211210549, 20211209775, 20211210159, 20211210610, 20211210555, 20211210733, 20211210408, 20211209880, 20211210133, 20211209816, 20211209782, 20211212088, 20211212082, 20211209679, 20211209740, 20211210588, 20211210670, 20211210824, 20211209912, 20211210350, 20211210141, 20211210585 and 20211210107.
headache; stuffy nose; sore throat; muscle aches; fever; chills; arthritis and her pain was more excruciating; This is a spontaneous report received from a contactable consumer(patient) via Medical Information Team.   A 50-year old female consumer reported for herself that she received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 Vaccine; Solution for injection; Lot number: ER8733; Expiry date: unknown) as a single dose for COVID-19 immunization via an unspecified route of administration in the left arm on 01Apr2021. The patients medical history and concomitant medications were not reported. The patient wanted to know if her reaction is common 4 days after receiving the vaccine. In 2021, The pati8ent had experienced with fever, chills, headache, and stuffy nose. She waned to know if her reaction is common 4 days after receiving the vaccine. On Follow up: the patients, Weight (kg): 90.72 and Height(cm): 157 were updated and the patient also experienced sore throat, fever, and muscle aches. It was unknown: Possible training facility for military. There were no other additional Vaccines administered on Same Date of the Pfizer Suspect. There was no emergency room visit or physician office visit for any of the events. There were no other vaccinations given prior to 4 weeks of the vaccine.The outcome for the events fever, stuffy nose, sore throat was not recovered. On 06Apr2021, chills and muscle aches were recovered. The outcome for headache and arthritis was unknown.
Two months after receiving the 2nd dose, I experienced pain in my left thumb. I went to the doctor and he sent me to a hands specialist. I received a cortisone shot as treatment.
A large raised red rash that was painful, itchy and hot to the touch over the vaccination site.
This is a spontaneous report from a contactable other hcp (Patient). A 44-year-old non-pregnant female patient received bnt162b2 (BNT162B2, Batch/Lot Number: ER2613) via an unspecified route of administration, administered in Arm Left on 17Mar2021 at 12:30 as DOSE 2, SINGLE for covid-19 immunisation. Medical history included, adenoma benign from an unknown date and unknown if ongoing Other medical history: papillary adenofibroma; infertility; quamous cell carcinoma (RLL) , infertility from an unknown date and unknown if ongoing Other medical history: papillary adenofibroma; infertility; squamous cell carcinoma (RLL), squamous cell carcinoma from an unknown date and unknown if ongoing Other medical history: papillary adenofibroma; infertility;squamous cell carcinoma (RLL), from an unknown date and unknown if ongoing Known allergies: NKDA. Concomitant medication(s) included levothyroxine sodium (SYNTHROID) taken for an unspecified indication, start and stop date were not reported.The patient had no covid prior vaccination and no covid tested post vaccination. Historical Vaccine included as bnt162b2 (BNT162B2, Batch/Lot Number: ER2613) via an unspecified route of administration, administered in Arm Left on 24Feb2021 at 02:30 PM as DOSE 1, SINGLE for covid-19 immunisation. On 15Mar2021, The patient experienced extreme fatigue, daily menstrual spotting for 90days and lack of menstrual period for 90 days. Doctor or other healthcare professional office/clinic visit required for events. Treatment reported as No. The outcome of the events was recovered on an unspecified date in 2021.
Patient experienced sweats on Friday morning, 1 day following the vaccine on Thursday. He felt fine the rest of the day on Friday and most of the day on Saturday. Sunday the patient started to vomit and have diarrhea. Monday he was feeling better but not 100% and he felt better on Tuesday. This patient had very similar adverse reactions as his wife (VAERS #165254), just occurring 2 days after her illness.
Shingles outbreak on face snd in left eye. Being treated currently with Valtrex and Lotemax SE.  I am generally very healthy. Suspect a correlation.
Fever and seizure 8 days after vaccination was administered. Had 2 more seizures with no fever one and two months later. Was then placed on antiseizure medication to control seizures.
Very dry nose or very congested/runny nose. Mostly dry, but occasionally very drippy. Crusted blood at nasal entrance, though no big bleed has currently occurred as of writing this.
Bells palsy; I have severe low blood sugar where I pass out 3 or 4 times a month; I have severe low blood sugar where I pass out 3 or 4 times a month; After shot blood sugar went to 350! Fasting 220; I have severe low blood sugar where I pass out 3 or 4 times a month; This is a spontaneous report from a contactable consumer (reported for herself). A 50-years-old female patient received a dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EW6206/Batch number was not reported), via an unspecified route of administration administered in the left arm on 03Jun2021 (at the age of 50-years-old) as unknown, single dose for COVID-19 immunization. Medical history included systemic lupus erythematosus from an unknown date and unknown if ongoing, ischaemia from an unknown date and unknown if ongoing and diabetes mellitus from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient previously received cafeine and experienced allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On an unspecified date in 2021, the patient experienced Bells palsy, she has severe low blood sugar where she pass out 3 or 4 times a month. After shot blood sugar went to 350, Fasting 220. She was always tested her blood daily for 10 plus years. She was still diabetic 3 months later and her blood sugar was extremely high. The reporter stated the events resulted in Doctor or other healthcare professional office/clinic visit. The patient underwent lab tests and procedures which included blood glucose abnormal: 350 on an unspecified date, blood glucose decreased: 220 on an unspecified date. Therapeutic measures were taken for the events with diabetic medication. The events Bells palsy, she has severe low blood sugar where she pass out 3 or 4 times a month assessed as serious (medically significant). The clinical outcome of the events was unknown.  Information on Lot/Batch number was available. Additional information has been requested.
Patient presents to the emergency department with complaint of generalized weakness that started this morning.  Patient states that he knows he does not feel well, but is unable to explain why.  Patient states he just feels sick and generalized weakness with nausea, but no vomiting.  Patient denies fever, chills, chest pain, cough, or shortness of breath.  Patient states that he just does not feel right.  Patient lives at home with a caregiver and is usually able to take care of most of his ADLs, now he finds it difficult to ambulate.  Patient complains of fatigue with generalized body aches
This spontaneous report as received from a registered nurse refers to an unknown number of patients of unknown age and gender. Relevant medical history and concomitant medication was not provided. On 23-OCT-2013 the patients were vaccinated with M-M-R II lot number J002505. Dose, route and frequency were not provided. On 23-OCT-2013, the patients were vaccinated with M-M-R II stored as high as 47F for up to 44 hours. No adverse effects were reported. This case was linked to MARRS case numbers 1311USA008054, 1311USA007704, 1311USA007705, 1311USA007695, 1311USA007696, 1311USA007699, 1311USA007700, 1311USA007701, 1311USA007702, 1311USA007698, 1311USA007697, 1311USA008057, 1311USA008058, 1311USA008059, 1311USA008060, 1311USA008055, 1311USA000906, 1311USA008061, 1311USA008056 (same reporter link). Additional information has been requested.
Pain, redness and swelling at right arm. Starting 8 hours after the injection. Patient came back on 10/18/18, and pharmacist advised her to take BENADRYL, TYLENOL and use cold pad.
Hot flashes, headache, fatigue chills, skin tingling, internal tingling throughout body, left arm/leg/mouth numbness, tingling, new onset anxiety, panic attacks.
high fever 101 degrees since Thursday 2-17-22, which responds to ibuprofen but has continued through to now. Pox-like rash on face, right side of neck and shoulder, abdomen, and back of left leg. Patient describes pain in RIGHT arm (opposite arm than what she received vaccine in) as excruciating. We have documented that she received the vaccine in her left arm and patient did confirm that she feels pain in the opposite arm. Fatigue that has continued through today.
I do not have full range of motion of my arm anymore without pain. I cannot sleep on it. I do not have much strength. After about 3 weeks I realized the pain is not going to go away so I went to see Dr on Nov 1st and she prescribed celebrex, lab work and X-ray. I do not know the outcome yet.
I received TDaP in L arm on 10/28/2020.  I'm a nurse practitioner and felt that it was given high in my arm at the time of injection and felt a weird sensation in my arm during injection but didn't think too much of it.  That night I had a restless night of sleeping because I couldn't get my arm comfortable when laying down but still didn't think too much about it. The next morning when I woke up my shoulder was in pain and I noticed I couldn't barely lift it much past my waist without pain. I was not able to put on my T shirt like normal or lift my arm over my head.  I still didn't think too much about it but as the day went on it continued to hurt and felt worse deep shoulder pain. Then I had a realization moment and said to my husband, I wonder if this shoulder pain is from the injection yesterday? It certainly seemed like it since there was no other aggravating factor or reason for the pain.  I took motrin and had some relief but still having deep, range of motion limiting pain in the shoulder and radiating up left neck. I am very concerned because I have never had any injury or issues whatsoever with my shoulder. And now looking back I felt I was right when I initially thought the injection was given high on my arm. When I removed the bandaid it was near the top of my arm, not in the main fleshy deltoid area.